Artículo científico Development and Validation of a Machine Learning Model for the Prediction of Bloodstream Infections in Patients with Hematological Malignancies and Febrile Neutropenia Gallardo-Pizarro, A.; Teijón-Lumbreras, C.; Monzo-Gallo, P.; Aiello, T.F.; Chumbita, M.; Peyrony, O.; Gras, E.; Pitart, C.; Mensa, J.; Esteve, J.; Soriano A., Garcia-Vidal C. Development and Validatio […]
Artículo científico Carga de la tos crónica refractaria o inexplicada en la vida de los pacientes: un estudio de cohorte Puente-Maestu L, Dávila I, Quirce S, et al. Burden of refractory and unexplained chronic cough on patients’ lives: a cohort study. ERJ Open Res 2023; 9: 00425-2023
Artículo científico Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Ann Oncol [Internet]. 2025;36(3):277–84.
Artículo científico Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials Lorcan P McGarvey, Surinder S Birring, Alyn H Morice, Peter V Dicpinigaitis et al. Lancet 2022; 399: 909–23
Artículo científico Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do-Youn Oh, Patricio Yañez et al. Lancet Oncol 2023; 24: 1181–95
Artículo científico Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial Spicer JD, Garassino MC, Wakelee H, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. Epub 2024 Sep 14.
Artículo científico Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic StemCell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC) José Luis Piñana, Estela Giménez, Lourdes Vázquez et al. Mediterr J Hematol Infect Dis 2024; 16; e2024065
Artículo científico Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Schmid et al. N Engl J Med. 2024. doi: 10.1056/NEJMoa2409932.
Artículo científico Test ePrints Power Automate – PDF T.K. Choueiri, P. Tomczak, S.H. Park et al. The New England journal of medicine. 2024; 390(15), 1359–1371.
Artículo científico First-Line Pembrolizumab 1 Chemotherapy Versus Placebo 1 Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826 Bradley J. Monk et al. JCO 2023;41, 5505-5511.
Artículo científico Test ePrints Power Automate – URL T.K. Choueiri, P. Tomczak, S.H. Park et al. The New England journal of medicine. 2024; 390(15), 1359–1371.
Artículo científico Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. N Engl J Med. 2024;390(10):875–88.